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Abstract 
This study examined the effects of pelvic radiation therapy on the levels of circulating 
pro-inflammatory cytokines (cPIC) in high-risk prostate cancer patients, who received 
pelvic radiation therapy delivered either by 3-dimensional radiation therapy pelvic (3D-
CRT) or intensity-modulated radiation therapy (IMRT). Subjects included 90 patients 
who had not previously received treatment for their prostate cancer, and who were 
planned to receive androgen deprivation therapy for three years, plus concurrent pelvic 
and prostate boost radiation therapy. Blood samples were drawn at least 3 months into 
androgen deprivation therapy, before initiation of pelvic 3D-CRT or IMRT (baseline), 
and on days 5 and 25 of radiation treatment. Samples were analyzed for TNF-α, INF-γ, 
IL-4, IL-6, IL-8 and IL-10. There were no significant differences between treatment 
groups for any of the cytokines at any time point. When the two treatment groups were 
combined into a single group, a significant time/dose effect was observed for IL-4 and 
INF-γ, which both significantly decreased from baseline to day 25, but the effect size of 
this change was small (0.30 and 0.24, respectively). There was no significant time effect 
for the other cytokines. These results suggest that in patients with high risk prostate 
cancer, receiving treatment with androgen deprivation therapy and pelvic radiation 
therapy, cPIC are not significantly altered in response to radiation therapy compared to 
baseline. The small but significant changes in IL-4 and INF-γ over time suggest a 
potential immunomodulating effect of radiation therapy. Further studies are needed to 
determine the potential of cPIC as biomarkers of radiation therapy toxicity.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Background and Rationale 
Prostate cancer is the most common cancer (excluding non-melanoma skin 
cancers) and the 3rd leading cause of death Canadian men (1). It is estimated that 21,300 
men will be diagnosed with prostate cancer in 2017, which represents 21% of all new 
cancer cases in men. Of these men, it is predicted that 4,100 will die from prostate cancer, 
amounting to 10% of all cancer-related deaths (1). 
Prostate cancer treatment options depend on several factors, such the extent of the 
disease, the stage of the cancer, the patient’s age, operability, co-morbidities, and overall 
health. For very low-risk prostate cancer patients, recommended treatment may involve 
active surveillance and regular follow-ups. In early stage, prostate cancer is curable with 
prostate excision surgery (radical prostatectomy) or local, prostate alone, radiation 
therapy, while adjuvant or salvage radiation therapy can be used following radical 
prostatectomy for residual disease or disease recurrence, respectively (2,3). Although 
surgery can be used in locally invasive, high risk prostate cancer, standard therapy for 
this disease involves prostate as well as pelvic lymph node RT in combination with 
androgen deprivation therapy delivered over 18-36 months (2,3). 
1.2 The Need for Biomarkers 
The risk for prostate cancer metastasis to distant sites and therefore, its response 
to local therapies, such as surgery and radiation therapy, is determined by the disease 
stage that is typically defined by the prostate specific antigen (PSA), clinical stage 
(TNM), and the pathologic Gleason score. The pre- and post-treatment value of prostate 
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specific antigen are used to predict survival rates and responses to radiation therapy (4). 
However, it is difficult to individualize treatments based on current pre-treatment factors, 
and there is no means to predict toxicity once radiation therapy has begun. Therefore, 
new, predictive biomarkers are needed in radiation oncology to predict toxicity and 
customize individual patients’ treatment (5,6). 
Over the past two decades, circulating pro-inflammatory cytokines (cPIC) have 
been investigated by researchers as a predictive biomarker of acute and late toxicity due 
to radiation therapy (6). The production and release of cytokines can be affected by the 
cancer itself, and treatments, such as radiation therapy, can cause inflammation, with 
subsequent release of cytokines in various tissues. High levels of circulating pro-
inflammatory cytokines have been associated with the development of toxicity, which 
can occur in irradiated normal tissues during treatment (7,8). Several studies have shown 
higher levels of circulating pro-inflammatory cytokines, such as interleukin-6 (IL-6), 
interleukin-8 (IL-8), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α), 
following radiation therapy. The prognostic relevance of circulating pro-inflammatory 
cytokines in different forms of cancer (soft-tissue and adult bone sarcoma, breast, 
pancreatic, gastric, kidney, lung cancer head and neck) are of significance to clinicians 
(7,8). However, few studies have examined the role of circulating pro-inflammatory 
cytokines in predicting radiation induced toxicity for prostate cancer patients (7) 
Therefore, the aims of the present study were: (a) to examine the effects of 
radiation therapy on the levels of circulating pro-inflammatory cytokines in high risk 
cancer patients that receive pelvic radiation therapy, and (b) to assess the viability of 
using the levels of circulating pro-inflammatory cytokines as potential biomarkers of 
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tissue toxicity. To this end, the levels of circulating pro-inflammatory cytokines were 
investigated in patients who participated in a randomized clinical trial that examined the 
impact of delivering pelvis radiation therapy via two protocols, intensity-modulated 
radiation therapy (IMRT), which was compared to 3-dimensional conformal radiation 
therapy (3D-CRT). 
This project was part of a larger clinical trial, which examined the potential of a 
modern radiation therapy technique (IMRT), aimed at reducing normal tissue toxicity as 
a means of improving patient quality of life. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Prostate Cancer 
The prostate gland is an ovoid shaped structure, composed of fibrous, granular 
and muscular elements. It is located in the pelvis, adjacent to the rectum, bladder, dorsal 
and periprostatic venous complexes, pelvic sidewall musculature, the pelvic plexus and 
cavernous nerves. The main function of the prostate is the production of seminal fluid, 
which protects and nourishes the sperm after ejaculation (2). 
Prostate cancer refers to the growth of abnormal cancer cells in the prostate. The 
majority of prostate cancers start in the prostate gland, and are referred to as 
adenocarcinoma (>95%). There are other types of cancer cells that start in the prostate, 
but adenocarcinoma is the most common (2,3). 
2.2 Screening and Diagnosis for Prostate Cancer 
The two tests commonly used to screen for prostate cancer are: the prostate 
specific antigen (PSA) blood test and the digital rectal exam. PSA is a protein produced 
by both normal and cancerous prostate cells that is released into the blood. High levels of 
prostate specific antigen are thought to be indicative of prostate cancer or non-cancerous 
inflammatory conditions.  
There is no specific normal or abnormal level of PSA in the blood. In the past, 
PSA levels of 4.0 ng/mL and lower were considered as normal. However, baseline PSA 
values vary widely amongst individuals, and some men with PSA levels below 4.0 ng/mL 
have prostate cancer, while men with higher levels have benign prostatic hyperplasia and 
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do not have prostate cancer. In addition, hormonal factors, inflammation, and even 
mechanical pressure on the prostate can cause the PSA level to fluctuate (2,3). 
2.2.1 Gleason score 
Prostate cancer tumours are graded using the Gleason scoring system, which 
evaluates architectural details of individual cancer glands, and describes five distinct 
growth patterns from Gleason 1 (well differentiated) to Gleason 5 (poorly differentiated). 
The two commonest growth patterns (primary and secondary) seen are submitted to give 
a final Gleason score(GS) ranging from 2 (1+1) to 10 (5+5) (Figure 1). 
 
 
Figure 1. Gleason’s Pattern. 
 
6 
 
2.2.2 TNM staging system 
Staging is a way of describing or classifying a cancer based on the extent of 
cancer in the body. The most common staging system for prostate cancer is the TNM 
system shown in Figure 2. TNM staging describes the size and extent of the primary 
tumour, the number and location of any regional lymph nodes that have cancer cells in 
them, and whether the cancer has spread or metastasized to another part of the body. For 
clinical staging prior to treatment, the extent of the tumour is described on the basis of 
clinical tests. Pathological staging describes the true extent of cancer in the prostate after 
it has been removed surgically (see Figure 2). 
 
Figure 2. TNM Staging system for prostate cancer  
(AJCC Staging Manual, 2010, 7th Edition) 
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The stage of the cancer refers to the extent of disease based on tumour location 
and size, and whether the cancer has spread outside the prostate gland to surrounding 
organs. Stages I and II refer to early-stage disease that is confined to the prostate. Stage 
III refers to locally advanced disease that has spread outside the prostate gland. Stage IV 
refers to cancer that has metastasized and possibly spread to the lymph nodes and other 
organs in the body. See figure 3. 
 
 
Figure 3. Anatomic stage/prognostic groups of Prostate cancer (AJCC Cancer 
Staging Manual, 2010, 7th Edition) 
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2.3 Role of Radiation Therapy  
Radiation therapy plays an important role in treating many forms of cancer (along 
with surgery and chemotherapy). Radiation therapy uses high energy ionizing rays (x-
rays or gamma rays) to destroy cancer cells by damaging the DNA within the cancer 
cells, thereby destroying the cells’ ability to divide and proliferate. Normal cells also 
sustain DNA damage, but they are able arrest their cell cycle in an organized fashion and 
repair their DNA (9). 
During radiation treatment, the dose of the radiation is escalated in a planned 
fashion to improve control of the radiation dose to the cancerous cells, and minimizing 
the dose to neighbouring cells (10,11). While radiation therapy dose escalation has 
improved local control of tumour growth, higher doses of radiation can lead to an 
increased toxicity to normal organs at risk, such as early and late gastrointestinal and 
genitourinary toxicity (11,12).  
Starting in late 1990’S, 3-dimensional conformal radiation therapy (3D-CRT) 
began to replace standard field radiation due to its benefits in focusing the radiation to the 
cancerous cells, thereby, reducing acute and late side effects to normal organs at risk. 
However, side effects remained, especially when employing high doses (13).  
Since the survival rate for most prostate cancer patients is generally greater than 
10 years, choosing a radiation therapy technique that minimizes radiation dose to 
surrounding healthy organs is important in improving patients’ quality of life (10,11). 
The challenge of increasing the radiation dose for prostate cancer treatment, while 
minimizing toxicity effects, has led to the development of new radiation therapy delivery 
techniques, one of which is intensity-modulated radiation therapy (IMRT) (14).  
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IMRT is a more modern technique that uses treatment fields with highly 
modulated radiation dose patterns to deliver exquisitely conformal radiation distributions. 
Rather than defining a fixed field shape with differential weighting, as is done in 
conventional treatment planning, IMRT treatment utilizes an inverse planning approach 
whereby the desired dose to the target and normal tissues is specified using mathematical 
descriptions referred as “constrains” or “objectives”, which define the principals 
according to which the radiation therapy plan is developed (2). IMRT for prostate 
radiation therapy delivers radiation from multiple angles using beams of different 
strengths, targeting a higher dose to the prostate and less to surrounding organs. Studies 
have shown that IMRT is associated with reduced long-term toxicities and excellent 
biochemical control outcomes compared to 3D-CRT (3). 
The ability of IMRT to reduce the dose applied to nearby organs at risk, without 
sacrificing coverage of the target structures, and perhaps improve target coverage, is 
clinically appealing, and has led to the rapid adoption of this technology for the treatment 
of prostate and other cancers (3). 
2.3.1 Different types of radiation techniques 
Radiation therapy is a treatment that has had a significant role in treating localized 
prostate cancer. Historically, radiation treatment has passed through different phases over 
time with considerable improvements in quality of radiation delivery (2,3). 
In modern radiation therapy, computed tomography/magnetic resonance imaging 
and sophisticated planning software are used to analyze and plan precise dose delivery 
and distribution to the target tumour and minimize radiation delivery to nearby organs at 
risk. This interaction between planning software and imaging has allowed the 
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development of more efficient conformal plans, which in turn prompted led to the 
development of 3D-CRT and IMRT (3).  
Radiation therapy is the standard of care curative therapy for localized early and 
advanced prostate cancer. It may be delivered in the form of external-beam radiation 
therapy or brachytherapy (i.e., the insertion of radioactive seeds into the prostate gland). 
Only external-beam radiation therapy techniques will be discussed here (3). 
Conventional external beam radiation therapy to the pelvis, with limited 
conformality, was the standard of radiation therapy care for many years and was typically 
delivered using a 4-field technique. The 4 fields (anteroposterior, posteroanterior, left 
lateral, and right lateral) were designed to include the prostate, the seminal vesicles, and 
the regional lymphatic vessels. Conventional external beam radiation therapy involved 
irradiation of large volumes of tissue, including the skin, small bowel, bladder, large 
bowel, pelvic bones, and additional areas of soft tissue, and therefore, it is not surprising 
that toxicity of normal tissues was problematic (2,3,4). Up to the early 2000s, external 
beam radiation therapy to the pelvis had limited conformality, and the radiation beam was 
shaped by using custom made lead blocks that were fitted on the radiation therapy unit to 
provide some limited conformality to the radiation beams. 
3D-CRT was developed when technological advances permitted the development 
of the multi-leaf collimator device, which permitted the generation of radiation therapy 
beams that were more conformal to the target. In 3D-CRT, the radiation beam is shaped 
to include the 3D anatomic configuration of the prostate and any specified adjacent tissue 
(including the seminal vesicles and periprostatic adventitial tissues). This technique 
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allows more precise delivery of the radiation therapy to the target organ or organs 
(2,3,15). 
IMRT is a relatively recent refinement of the 3D-CRT technique. IMRT uses 
treatment fields with highly irregular radiation intensity patterns to deliver exquisitely 
conformal radiation distributions. IMRT can achieve tightly conformal dose distributions 
through the use of non-uniform radiation beams. The intent of this form of therapy is to 
create highly conformal fields by treating the patient with multiple static portals or 
dynamically modulated fields (so-called step-and-shoot IMRT) at specific angles. 
Delivery of IMRT requires a computer-controlled beam shaping apparatus on the linear 
accelerator, known as multi-leaf collimator. The multi-leaf collimator used for IMRT 
consists of many small individually moving leaves that can create multiple beam shapes 
(3,15). 
 
2.3.2 Role of androgen deprivation therapy on prostate cancer 
Androgen deprivation therapy is the cornerstone of medical treatment for 
advanced prostate cancer and is used as a neoadjuvant, concurrent, and adjuvant therapy 
for high risk disease (16,17). The growth of the prostate gland is regulated by androgens. 
The primary androgen being testosterone. Generally, androgens are required for the 
development of prostate cancer, and changes in androgen activity over time can affect 
carcinogenesis and disease progression (2). 
The purpose of androgen deprivation therapy is to block the production of 
testosterone, and it is a well-established treatment for advanced prostate cancer (17). 
Androgen deprivation therapy has been increasingly used in combination with radiation 
therapy in high risk prostate cancer patients (16,17). 
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There are many options of using androgen deprivation therapy, but the following 
are the most popular. Surgical removal of one or both of the testicles (orchiectomy) to 
prevent testosterone production. This is very effective in that is can reduce the level of 
testosterone by 90-95% but is not often used because of its permanent effect. Another 
option is medical castration with gonadotropin releasing hormone agonists. Long-term 
treatment with gonadotropin releasing hormone agonists supplant the effect of the 
pulsatile release of endogenous gonadotropin releasing hormone, and is thought to down-
regulate its receptors in the pituitary gland, leading to castration levels of testosterone 
within 3 weeks (2,3). 
Androgen deprivation therapy has been increasingly used in combination with 
radiation therapy in the treatment of intermediate to high risk prostate cancer. The current 
standard of care for patients diagnosed with high-risk prostate cancer confirmed by 
histology is the combination of neoadjuvant, concurrent and adjuvant androgen 
deprivation therapy (for a total of 3 years) and radical radiation therapy. Luteinizing 
hormone-releasing hormone agonists are long-acting analogs of the native luteinizing 
hormone-releasing hormone peptide and are effective at reducing serum testosterone. 
Androgen deprivation therapy has been shown to improve the survival rate when 
combined with radiation therapy. Bolla et al. (2002) showed that long term androgen 
suppression with luteinizing hormone-releasing hormone agonist improves 5 year 
survival rate to 78%, compared to 62% with radiation therapy alone (17). 
 
2.3.3 Current standard of care for high risk Prostate cancer 
High risk prostate cancer is defined as a tumour of any stage (T1-T4) with a 
Gleason score of 8-10, or a PSA above 20, or a tumour determined to be stage T3 or 
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higher. The current standard of care for high risk prostate cancer has been the use of 
hormonal therapy, in a neo-adjuvant, concurrent and adjuvant setting, in combination 
with radiation therapy. 
 
2.4 Radiation Therapy Toxicity in Prostate Cancer Patients 
Regardless of the radiation mode used, radiation therapy for prostate cancer can 
cause major acute or late side effect complications to the surrounding normal organs at 
risk (18). Acute toxicity occurs when the side effects of radiation therapy occur less than 
12 weeks from the completion of the treatment. Late toxicity occurs when the side effects 
occurred after 12 weeks of the completion of the treatment. Gastrointestinal and 
genitourinary toxicity are the most important complications and can lead to life 
threatening conditions. Dose escalation with 3D-CRT improves the biochemical control 
of prostate cancer, but it can lead to acute and late toxicity to normal organs at risk. 
Several studies have suggested that IMRT reduces the radiation dose to the 
normal organs at risk, leading to lower rates of acute and late toxicity, even at high dose 
escalation (>74 Gray (Gy)) (19-21). Mamgani et al. compared the acute and 
gastrointestinal and genitourinary toxicity in prostate cancer patients to a total dose 78Gy 
delivered via 3D-CRT or IMRT techniques. The results show that IMRT reduced the 
toxicity without compromising the outcome in patients (11). Zelefsky et al. also showed 
the benefit of high-dose IMRT for patients with localized prostate cancer with respect to 
dose conformality relative to tumor coverage and exposure to normal organs. The authors 
concluded that IMRT represents the safest technique when using higher radiation doses in 
prostate cancer (18). Mok et al. showed that IMRT allowed for the delivery of high 
conformal radiation therapy to the target volume, while lowering the dose to surrounding 
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organs at risk, compared to 3D-CRT (20). Fenoglietto et al. concluded that the dose 
coverage of the planned target volume and organs at risk was better with IMRT and 
remained so, even when the internal volume changed (12). 
In a recent meta-analysis, Yu et al. evaluated 23 eligible studies involving ration 
therapy with prostate cancer (13). IMRT was shown to result in a decreased grade 2-4 for 
both acute and late acute gastrointestinal toxicity, and late rectal bleeding compared with 
3D-CRT. However, the study also showed that IMRT increased grade 2-4 tumours in 
terms of both acute and late genitourinary toxicity. The study concluded that generally, 
IMRT provides better biochemical control than 3D-CRT (13). In another recent, 
randomized clinical trial, Viani et al. reported that the percentage of the bladder and 
rectal volume receiving doses between 54 Gy to 62 Gy was statistically lower for IMRT 
versus 3D-CRT, and resulted in a reduced acute/late grade >2 gastrointestinal and 
genitourinary toxicity compared to 3D-CRT (21). The authors concluded that this study 
provided further support to the idea that reduced dosage to the normal organs at risk 
using IMRT provides clinical benefits to prostate cancer patients. 
 
2.4.1 Biomarkers of toxicity 
Understanding the biologic events associated with gastrointestinal and 
genitourinary toxicity in patients receiving pelvic radiation therapy can help researchers 
understand the mechanisms leading to the development of this toxicity. Further, 
identifying biomarkers that could predict the development of toxicity in patients that are 
being treated with radiation therapy would have significant benefits for patients, and 
possibly allow for individualized treatment plans. The focus of the present study was to 
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examine whether circulating pro-inflammatory cytokines can serve as potential markers 
of toxicity, prior to and during radiation therapy delivered by two different protocols. 
 
2.5 Cytokines 
Cytokines are a large group of proteins, peptides or glycoproteins that are secreted 
by certain cells of the immune system. They are a category of hormone-like factors that 
mediate and regulate immunity, inflammation, and hematopoiesis (22). Cytokines can 
have either pro- or anti-inflammatory and immunosuppressive activity, depending on the 
microenvironment. A cytokine network is shown in Figure 4 below.  
Cytokines are affected by the cancer itself. The tumour microenvironment is rich 
in cytokines and other inflammatory mediators that influence immunosuppression, 
growth of cancer cells, tissue remodelling, and angiogenesis (7,23,24). Cytokine is a 
general name; other names include lymphokine (cytokines made by lymphocytes), 
monokine (cytokines made by monocytes), chemokine (cytokines with chemotactic 
activities), and interleukin (cytokines made by one leukocyte and acting on other 
leukocytes). Cytokines may act on the cells that secrete them (autocrine action), on 
nearby cells (paracrine action), or in some instances on distant cells (endocrine action) 
(6,23). 
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Figure 4. Cytokine network (Kyoto Encyclopedia of Genes and Genomes, 
www.genecopoeia.com) 
 
 
2.5.1 Association of pro-inflammatory cytokines with radiation therapy in cancer  
While the mechanisms responsible for late side effects of radiation therapy are 
largely unknown, it is believed that circulating cytokines are involved in the mediation of 
radiation therapy toxicity. Furthermore, there is significant interest in the potential use of 
circulating cytokine levels as predictive biomarkers of the side effects of radiation 
therapy (8,23,25). More recently, elevated pro-inflammatory and pro-fibrotic cytokines 
have been observed in the plasma of patients receiving radiation therapy, thereby 
providing additional support for the existence of a humoral response to radiation therapy 
(26). Abnormal levels of cytokine production induced by radiation have been suggested 
as being a contributing factor by multiple investigators. It has been recently shown that 
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ionizing radiation can increase the expression of these cytokines, and there are 
indications that increased levels of cytokines may be associated with morbidity (23). 
Rubin et al. (25) were among the first researchers to describe the role of cytokines 
related to radiation toxicity. In pre-clinical and clinical lung studies, they showed that the 
levels of IL-1, transforming growth factor (TGF)-β, and TNF-α were increased 
immediately after radiation exposure, and that chronically elevated TGF-β levels were 
associated with an increased risk of pulmonary fibrosis. 
The concept of using cytokine expression during radiation therapy as a predictive 
biomarker of toxicity outcomes is promising (45,47). In a study focused on thoracic 
radiation therapy, the circulating pro-inflammatory cytokines, IL-1a and IL-6 and the 
profibrotic cytokine TGF-β, were linked to the temporal development of radiation-
induced inflammatory pneumonitis and pulmonary fibrosis, respectively (27). Seruga et 
al. list several studies describing the levels of circulating pro-inflammatory cytokines in 
different types of cancer (see Table 1). Significantly, higher levels of IL-6, IL-8 and IL-
10 were observed in breast cancer, pancreatic cancer, soft tissue sarcoma, and adult bone 
sarcoma. In addition, high levels of IL-6, and IL-8 were found in head and neck cancer. 
In gastric cancer, IL-6 was also high, indicating a higher stage of the disease. This study 
did not report any studies for prostate cancer and Hodgkin lymphoma (7). 
 
Table 1. Observational studies of levels of circulating cytokines and their prognostic 
significance in cancer (adopted from Seruga et al., 2008). 
 
Type of 
Cancer 
Number 
(Setting) 
Reported changes in circulating levels of 
Cytokines 
Prognostic Significance Ref. 
 
Soft-tissue 
sarcoma 
145 (non-metastatic) 
50 healthy controls 
Significantly higher levels of IL1RA, sIL2R, 
IL6, IL8, IL10, TNFRI, TNFRII, TNFα , M-
CSF, FGF2 and VEGF than controls 
NO 19 
Adult bone 
sarcoma 
72 (non-metastatic) 
50 healthy controls 
22 controls with 
Significantly higher levels of IL6, IL8, L10, 
VEGF, FGF2, M-CSF, IL1RA, TNFRI and 
TNFRII than healthy controls; significantly 
Higher levels of IL1RA and 
TNFRI are an independent 
predictor of shorter OS  
20 
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benign tumors higher levels of IL6, IL8, IL1RA, TNFRI and M-
CSF than in patients with benign bone tumors   
Breast 
cancer 
111 (non-metastatic) 
36 healthy controls 
Significantly higher levels of IL6 than in healthy 
controls 
NA 21 
45 (non-metastatic 
and metastatic) 
25 healthy controls 
Significantly higher levels of IL6, IL8 and IL10 
than in healthy controls. Patients with higher 
stages (stage III and IV) had higher levels of 
cytokines compared with patients with stage II  
NA 209 
96 (progressive 
metastatic) 
Significantly higher levels of IL6 in patients with 
higher burden of metastatic disease than those 
with lower burden 
Higher levels of IL6 are 
associated with shorter OS 
206 
65 (recurrent) 
17 (non-recurrent) 
Significantly increased levels of IL6 in people 
with recurrent breast cancer compared with non-
recurrent breast cancer 
NA 210 
77 (metastatic) 
64 (non-metastatic) 
27 healthy controls 
Significantly higher levels of IL8 in non-
metastatic and metastatic disease compared with 
healthy controls, and in metastatic disease as 
compared with non-metastatic disease  
Higher levels of IL8 are an 
independent predictor of 
shorter OS in women with 
metastatic disease 
22 
Pancreatic 
cancer 
51 (non-metastatic) 
48 healthy controls 
Significantly higher levels of IL6, IL8, IL10 and 
IL1RA than in healthy controls 
High levels of IL6 are an 
independent predictor of 
shorter OS 
23 
Gastric 
cancer 
155 (non-metastatic) 
63 healthy controls 
Higher levels of IL6 than in healthy controls 
Higher levels of IL6 associated with a higher 
stage of the disease 
Higher levels of IL6 are an 
independent predictor of 
shorter OS 
24 
Kidney 
cancer 
64 (non-metastatic) 
12 controls with 
benign tumors 
Significantly higher levels of IL6 and IL10 than 
in  
patients with benign disease at diagnosis and 3 
months after resection of the primary tumor 
NA 25 
138 (metastatic) IL6 detectable in 70%, IL10 in 8% and VEGF in 
71% of patients, respectively 
Higher levels of IL6 are an 
independent predictor of 
shorter PFS and OS 
207 
Prostate 
cancer 
423 (non-metastatic) Not reported Preoperative levels of sIL6R 
and TGFβ increased the 
accuracy of classical 
nomogram to predict 
biochemical recurrence 
208 
Head and 
neck cancer 
40 (non-metastatic) 
20 healthy controls 
Significantly higher levels of IL6 and IL8 than in 
healthy controls 
NA 26 
11 (non-metastatic) 
12 controls with 
benign tumors  
12 healthy controls 
Significantly higher levels of IL6, IL8 and 
VEGF than in healthy controls and patients with 
laryngeal papilloma 
NA 243 
58 (non-metastatic) Significantly higher levels of IL6 and IL10 and 
lower levels of IL12 in patients with higher 
tumor and node stage of primary tumor 
NA 211 
57 (non-metastatic) 
40 healthy controls 
Significantly higher levels of IL10 and lower 
levels of IL12 than in healthy controls; higher 
IL10 levels associated with higher tumor stage 
NA 27 
Hodgkin 
lymphoma 
519 (at diagnosis) Not reported High levels of IL1RA and 
IL6 are an independent 
predictor of shorter EFS 
244 
AML, MDS 198 (at diagnosis) 
48 healthy controls 
Significantly increased levels of TNFα , IL1RA, 
IL6 and IL10 than in healthy controls 
Higher levels of TNFα was 
associated with lower CR 
rate, EFS and OS (not an 
independent prognostic 
factor) 
28 
54 (at diagnosis) 
NS healthy controls 
Significantly higher levels of IL1, IL1RA, IL6, 
IL8 and TNFα than in healthy controls 
NA 109 
AML, acute myeloid leukemia; CR, complete remission; EFS, event-free survival; FGF2, fibroblast growth factor 2; IL, interleukin; 
IL1RA, IL1 receptor antagonist; M-CSF, macrophage-colony stimulating factor; MDS, myelodysplastic syndrome; NA, not assessed; 
NS, not stated; OS, overall survival; PFS, progression-free survival; sIL2R, soluble IL2R; TNF, tumor necrosis factor; TNFR, TNF 
receptor; VEGF, vascular endothelial growth factor. 
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2.5.2 Association of pro-inflammatory cytokines with radiation therapy in prostate 
cancer 
Limited studies have been done so far to examine the levels of cytokines in 
patients with prostate cancer (7,44). Cytokine expression is associated with radiation-
related organ damage and may be useful to help predict toxicity. Christensen et al. 
observed that IL-6, IFN-γ, IL-1, and IL-2 may be important cytokine biomarkers of acute 
gastrointestinal and genitourinary toxicity (28). In contrast, a relatively recent study by 
Dirksen et al. suggest that there is no strong correlation between radiation therapy 
induced symptoms (urinary irritative, bowel problems, etc.) and cytokine levels (29). 
Patients undergoing 3D-CRT for prostate cancer had an increase in circulating IL6 levels 
within 15 days of radiation therapy, which returned to baseline levels soon after. In 
contrast, IL-2, IL-4, IL-5, TNF-α, macrophage inflammatory protein 1-alpha, and 
leukemia inhibitory factor levels were unchanged with radiation therapy (30). Kovacs et 
al. found elevated circulating cytokines (P<0.05), even prior to radiation therapy, which 
increased even higher during radiation therapy (26). This work forms the basis for the 
development of a prospective radiation therapy trial in which IL-6, IFN-γ, IL-1, and IL-2 
are assessed as potential biomarkers of radiation toxicity, which could ultimately alter 
patient management during radiation therapy. 
 
2.5.3 Impact of androgen deprivation therapy on pro-inflammatory cytokines 
According to the literature, androgens tend to be immunosuppressive in nature 
(30). Studies have examined the role of androgen deprivation therapy on circulating 
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cytokine levels. Jonke et al. examined the levels of circulating cytokines in two patient 
groups: one receiving radiation therapy alone, and the other receiving radiation therapy + 
androgen deprivation therapy.  The results showed that while the cytokine response was 
similar between both groups, the magnitude of the cytokines levels was noticeably 
different between the two groups, with IL-1β and IL-6 being higher in patients receiving 
radiation therapy + androgen deprivation therapy compared to radiation therapy alone, 
while TGF-β was lower in patients receiving radiation therapy + androgen deprivation 
therapy compared to radiation therapy alone. The authors further mentioned that 
androgen deprivation therapy may shift the ratio of pro-inflammatory and profibrotic 
cytokines toward a more immune-stimulatory state (30). 
Maggio et al. examined 3 groups of men: 1) 20 men with prostate cancer 
undergoing androgen deprivation therapy for at least 12 months prior to the onset of the 
study (androgen deprivation therapy group); 2) 18 age-matched men with non-metastatic 
prostate cancer who had undergone local surgery and/or radiation therapy, but had not yet 
received androgen deprivation therapy and were eugonadal (non-androgen deprivation 
therapy group); and 3) 20 age-matched healthy eugonadal men (control group). They 
found that no significant differences in serum levels of pro-inflammatory or anti-
inflammatory cytokines between the 3 groups. These data suggest that men with prostate 
cancer undergoing long-term androgen deprivation therapy do not have elevated levels of 
pro-inflammatory cytokines compared to age and disease matched controls (32). 
Furthermore, a recent study by Tanji et al. showed that androgen deprivation therapy, in 
combination with radiation therapy, influenced certain pro-inflammatory cytokine levels 
in prostate cancer patients as evidenced by significantly increased levels of epidermal 
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growth factor (EGF), granulocyte-colony stimulating factor (G-CSF), and IFN-γ during 
radiation therapy (33). Both these studies report that the immunological responses to 
androgen deprivation therapy alone, or in combination with radiation therapy, are not 
well understood, and that more research is needed in this area.  
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CHAPTER 3: OBJECTIVES AND 
HYPOTHESIS 
 
3.1 Overall purpose 
 
There is a need to identify potential blood borne biomarkers in pre-treatment or 
early treatment blood samples that can reliably predict radiation therapy induced 
gastrointestinal and genitourinary toxicity in high risk prostate cancer patients. 
Circulating pro-inflammatory cytokines levels in the blood show some promise as 
potential clinical biomarkers. If specific circulating cytokine levels prior to, or during, 
radiation therapy are found to be statistically associated with gastrointestinal and 
genitourinary toxicity, then patients could be identified early, targeted for specific 
intervention, including modification of radiation dose, and followed closely post-
treatment. 
One way to investigate this issue further is to measure cytokine levels in high risk 
prostate cancer patients who have received either 3D-CRT or IMRT. Thus, the overall 
purpose of the present study was to compare cytokine levels in the pre-treatment and 
early treatment blood samples of patients receiving IMRT vs 3D-CRT pelvic radiation 
therapy for high risk prostate cancer. 
 
3.1.1 Specific Objectives  
The specific objectives of this project were:  
i) to examine how pelvic radiation therapy for high risk prostate cancer patients 
influences the levels of circulating pro-inflammatory cytokines; 
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ii) to determine whether the circulating pro-inflammatory cytokines response to 
pelvic radiation therapy differs amongst patients treated with 3D-CRT vs IMRT. 
3.1.2 Hypothesis 
The central hypothesis is that there will be statistically significant higher levels of 
circulating pro-inflammatory cytokines in patients that received 3D-CRT compared to 
IMRT for the same radiation dose to the pelvis.   
 
3.2 Long-term Goals 
The current project is part of a larger clinical trial, the long-term goal of this 
research is to determine: i) whether circulating pro-inflammatory cytokines levels are 
closely associated with radiation therapy dose delivered to organs at risk and patient 
quality of life, and ii) whether circulating pro-inflammatory cytokines levels can be used 
as predictive biomarkers of radiation therapy toxicity during pelvic radiation therapy for 
prostate cancer.  
To achieve this goal, it is necessary to examine cytokine levels over time, i.e., 
prior to initiating treatment, and over the course of early radiation therapy, and correlate 
these results with dosimetry parameters, toxicity assessments, and measures of patient 
quality of life. 
The results of the present study are important in the treatment of cancer as the results 
could lead to the development of individually tailored radiation therapy treatment for 
prostate cancer. The goal would be to develop treatment to provides improved local 
control and the preservation of the patients’ quality of life.  
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CHAPTER 4: METHODS 
 
4.1 Study Population  
The procedures involved in this study received ethics approval from both the 
Juravinski Cancer Center and Brock University Research Ethics Boards. One hundred 
and four patients, who had not previously received treatment for their prostate cancer, 
were accrued to the larger clinical trial. Eligibility for the clinical trial was based on a 
diagnosis of high-risk adenocarcinoma of the prostate, confirmed by histology (the 
UICC-TNM staging system was used) and defined as tumours with one or more of the 
following criteria: a tumour of stage T1-T4 with a Gleason score of 8-10, or a PSA above 
20, or a tumour determined to be stage T3 or higher. Participating patients have not 
previously received treatment for their prostate cancer. Patients also received hormone 
therapy (neoadjuvant, concurrent and adjuvant for 2 to 3 years).  
Of all the 104 patients who agreed to participate in the study and provided 
informed consent, only 90 patients agreed to have their blood samples collected (the other 
14 declined this portion of the trial). From the 90 patients involved in the present study, 
blood samples from 75 patients – 35 treated with 3D-CRT (mean age 70 ± 12.9), and 40 
patients treated with IMRT (mean age 68 ± 19.0), were collected and analyzed for 
cytokine levels over the course of their radiation treatment. The remaining samples 
(n=15) were not analyzed due to technical and storage issues (see Figure 5).  
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Figure 5. Study Protocol, including patient randomization. 
 
Based on their prostate cancer characteristics shown in Table 2, all patients 
participated in the clinical trial were randomly assigned (1:1 ratio) to one of the treatment 
groups (Figure 5): Group 1: Received 3D-CRT and neoadjuvant, concurrent, and 
adjuvant hormones with standard radiation therapy consisting of 4500cGy in 25 fractions 
to the pelvic nodes using standard 4 field conformal radiation therapy, followed by a 
High risk adenocarcinoma of the prostate 
Inclusion (N=104) 
Consent for biospecimens (N=90) 
Neoadjuvant, concurrent and adjuvant 
hormonal therapy 
Exclusions 
No consent 
Randomization (1:1) 
Phase 1: Pelvic nodes using 4 field conformal 
4500cGy/25 fractions 
Phase 1: Pelvic nodes using IMRT                              
4500cGy/25 fractions 
Phase 2: Prostate boost using IMRT                   
2496/13 fractions 
Phase 2: Prostate boost using IMRT                   
2496/13 fractions 
Outcome Analysis (N=75) 
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prostate boost of 2496cGy using IMRT; Group 2: Received IMRT and neoadjuvant, 
concurrent, and adjuvant hormones, and pelvic nodal irradiation using IMRT consisting 
of 4500cGy in 25 fractions to the pelvic nodes, followed by a prostate boost of 2496cGy 
using IMRT. 
 
Table 2. Baseline prostate cancer characteristics of all patients in the clinical trial. 
Characteristic IMRT 3D-CRT Total 
Number of patients 52 52 104 
Clinical Stage N % N % N 
Unknown 4 3.8 6 5.8 10 
T1 13 12.5 14 13.5 27 
T2 27 26.0 19 18.3 46 
T3 7 6.7 12 11.5 19 
T4 1 1.0 1 1.0 2 
PSA value 
     
≤ 10 15 14.4 15 14.4 30 
11-20 15 14.4 14 13.5 29 
>20 22 21.2 23 22.1 45 
Gleason Score 
     
6 1 1.0 2 1.9 3 
7 18 17.3 19 18.3 37 
8-10 33 31.7 31 29.8 64 
 
 
4.2 Blood collection phase 
The blood collection phase was completed, and the samples stored, at the 
Juravinski Cancer Centre by trained personnel. As shown in Figure 6, each patient was 
asked to provide three blood samples: the initial sample at the time of radiation therapy 
simulation (pre-radiation therapy – day 0) and on days 5 (9 Gy) and 25 (45 Gy) of their 
pelvic radiation therapy. Days 5 and 25 of radiation therapy were selected on the basis of 
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the descriptions of both early and late waves of circulating cytokine expression during 
pelvic radiation in previous studies (26,29). 
Peripheral blood was drawn from each patient. Standard operating procedures for 
serum sample collection and EDTA plasma preparation were followed for the blood 
collection and isolation of EDTA plasma. Blood was collected into BD Vacutainer®, 
Lavender top tubes containing clot activator and gel from serum separation. Blood 
samples were processed for plasma isolation (3000xg spin at 4oC) within 30 min at the 
Juravinski Cancer Centre Clinical Trials Laboratory. All cryotubes were coded and 
samples were stored at -80 °C until analysis. 
 
 
 
0           1           2             3          4            5              6          7    8 
                                                                                              
Day 0             Day 5                                                                              Day 25          
 
Figure 6. Schematic of sample collection. 
 
 
 
The serum samples were placed in a specimen transport box containing dry ice, 
and transported from the Juravinski Cancer Centre to the Cairns Family Health and 
Bioscience Research Complex at Brock University for analysis. The serum samples were 
analyzed for several pro-inflammatory and anti-inflammatory cytokines.  
 
PHASE 1                                                                                                              PHASE 2 
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4.3 Cytokine analysis 
Inflammatory cytokines, including TNF-α, INF-γ, IL-4, IL-6, IL-8 and IL-10, were 
analyzed in duplicate, using 6 Milliplex MAGPIX kits (MILLIPLEX MAP Human 
Cytokine/Chemokine Magnetic Bead Panel - Immunology Multiplex Assay). All assays 
were performed according to the manufacturer’s instructions. The use of Milliplex kits 
allows for efficient use of time, as several markers can be measured on the same plate. 
Serum was diluted according to kit-specific instructions (see Appendix x). All samples 
and kits were brought to room temperature prior to the initiation of the analysis 
procedure. All analyses were performed in duplicate. Assays were processed over two 
days. On the first day, all reagents were brought to room temperature and reconstituted. 
When completed, the plate was sealed with a plate sealer, wrapped in foil, and left to 
incubate for 16-18 hours on a plate shaker at 4˚C. The following morning, all remaining 
reagents were removed from the fridge and allowed to warm to room temperature. 
Cytokine concentrations on each plate were read using xPONENT ® software for the 
MAGPIX ® analyzer. The intra-assay coefficients of variation for the 6 plates were 10.3, 
9.2, 8.7, 6.6, 7.2 and 9.8%, yielding an average intra-assay coefficient of variation of 
8.6%. The inter-assay coefficient of variation was calculated by running two quality 
controls (1 high and 1 low) on each plate and averaging the coefficients from both quality 
controls from each plate, yielding an average inter-assay coefficient of variation of 7.1%. 
 
4.4 Statistical Analysis 
Statistical analyses were performed using SPSS version 23 for Windows and 
GraphPad Prism 5, SAS Version 9. For all analyses, a p-value ≤ 0.05 was taken as 
significant. The normality of the dependent variables (inflammatory markers) was 
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assessed by evaluating three criteria: (i) histogram shape, (ii) Kolmogorov-Smirnov 
normality tests, and (iii) z-scores for skewness and kurtosis values. Data were not 
normally distributed for any dependent variable, as histograms were not symmetrical in 
most cases, normality tests failed, and the z-scores for skewness and kurtosis were 
outside the accepted range of ± 2.5. As a result, it was decided to use non-parametric tests 
for the analysis of the cytokine levels.  
For the non-parametric analysis, Mann-Whitney tests were used to assess 
differences in the levels of the inflammatory markers between treatment groups. As no 
significant differences were found at baseline (day 0) between the groups, the groups 
were combined for further analysis. To assess changes over time in inflammatory 
markers for days 0, 5, and 25, a Friedman test for repeated measures was conducted. In 
case a significant time effect was detected, a Wilcoxon signed-rank test was used for post 
hoc pair-wise comparisons.  
Significance was assumed at an alpha level of 0.05 for all tests. Effect sizes (ES) 
were calculated for the post hoc pair-wise comparisons by the following formula: r = z / 
√n, where n = number of observations over the two times points. To examine effect size, 
the Cohen (1988) criteria were applied – where a value of 0.1 represents a small effect, 
0.3 represents a medium effect, and 0.5 represents a large effect (27). 
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CHAPTER 5: RESULTS 
5.1 Differences between 3D-CRT and IMRT (Treatment Effect) 
 
Table 3 shows the concentrations of the various circulating pro-inflammatory 
cytokines at days 0, 5, and 25. The Mann-Whitney tests revealed that there were no 
significant differences (p>0.05) between the two groups (3D-CRT and IMRT) in the 
levels of inflammatory markers (IL-4, IL-6, IL-8, IL-10, TNF-α, INF-γ) at any time point 
(day 0, day 5 and day 25).   
Table 3: Mann-Whitney tests for the group differences in the levels of circulating pro-
inflammatory markers (cPIC) at each time point (day 0, day 5 and day 25). 
 
cPIC 
Markers 
(pg/ml) 
Groups 
Time Points (days) 
Pre-Treatment Day 0 Day 5 Day 25 
Mean ± SEM 
Median, N 
M-W U 
Z(p) 
Mean ± SEM 
Median, N 
M-W U 
Z(p) 
Mean ± SEM 
Median, N 
M-W U 
Z(p) 
IL-4 
3DCRT 
45.9 ± 8.0 
30.9, 28 431 
-0.64 
(0.52) 
41.9 ± 7.4 
26.0, 30 509 
-0.21 
(0.83) 
37.1 ± 7.3  
22.9, 28 506 
0.22 
(0.82) IMRT 
38.7 ± 5.4 
26.9, 34 
39.9 ± 7.8  
25.3, 35 
35.7 ± 4.8  
30.1, 35 
IL-6 
3DCRT 
2.8 ± 0.5 
2.1, 27 429 
0.62 
(0.54) 
2.7 ± 0.3 
2.3, 29 393 
-0.84 
(0.40) 
2.8 ± 0.5 
1.8, 29 507 
0.62 
(0.53) IMRT 
3.2 ± 0.5 
2.5, 29 
3.0 ± 0.6 
1.4, 31 
3.5 ± 0.6 
2.2, 32 
IL-8 
 
3DCRT 
7.1 ± 2.6  
4.1, 33 661 
0.40 
(0.69) 
6.2 ± 1.8 
3.6, 35 657 
0.09 
(0.93) 
7.8 ± 2.6 
4.2, 34 664 
0.20 
(0.84) IMRT 
5.2 ± 0.7 
3.8, 38 
4.6 ± 0.5 
4.0, 38 
5.6 ± 0.7 
4.4, 38 
IL-10 
3DCRT 
14.9 ± 2.2 
11.8, 22 259 
0.98 
(0.33) 
13.4 ± 2.2  
8.7, 23 281 
0.93 
(0.35) 
12.9 ± 2.4  
9.2, 19 256 
0.13 
(0.13) IMRT 
19.7 ± 3.2 
14.2, 20 
19.9 ± 3.9  
13.4, 21 
18.3 ± 2.6  
14.9, 21 
TNF-α 
3DCRT 
4.1 ± 0.4 
3.8, 29 456.5 
-0.50 
(0.61) 
4.0 ± 0.3 
3.7, 29 482.5 
-0.15 
(0.88) 
3.8 ± 0.3 
2.9, 30 581 
1.42 
(0.16) IMRT 
4.3 ± 0.6  
3.6, 34 
4.8 ± 0.7 
3.3, 34 
4.80 ± 0.6  
4.05, 32 
INF-γ 
3DCRT 
10.5 ± 1.3  
9.4, 30 609 
0.48 
(0.63) 
10.6 ± 1.3 
9.2, 33 679 
0.40 
(0.69) 
10.5 ± 1.5 
7.8, 29 
604 
0.47 
(0.64) 
 IMRT 
15.9 ± 2.9  
9.8, 38 
16.1 ± 3.2  
9.8, 39 
15.4 ± 2.8 
9.3, 39 
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There was high individual patient variability in the cytokine concentration values 
as shown by the individual line graphs for each treatment group (see Figures 7-18). For 
all 6 cytokines, the variation in cytokine concentration was one or more orders of 
magnitude.  
 
Figure 7. 3D-CRT Group. IL-4 cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median 
values 
 
 
Figure 8. IMRT Group. IL-4 cytokine concentration (pg/ml) for all participants 
(n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
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Figure 9. 3D-CRT Group. IL-6 cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
 
 
 
Figure 10. IMRT Group. IL-6 cytokine concentration (pg/ml) for all participants 
(n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
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Figure 11. 3D-CRT Group. IL-8 cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
 
 
  
 
Figure 12. IMRT Group. IL-8 cytokine concentration (pg/ml) for all participants 
(n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
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Figure 13. 3D-CRT Group. IL-10 cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
 
 
Figure 14. IMRT Group. IL-10 cytokine concentration (pg/ml) for all 
participants (n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median 
values. 
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Figure 15. 3D-CRT Group. TNF-α cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
 
 
Figure 16. IMRT Group. TNF-α cytokine concentration (pg/ml) for all 
participants (n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median 
values. 
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Figure 17. 3D-CRT Group. IFN-γ cytokine concentration (pg/ml) for all 
participants (n=35) at all time points (Day 0, 5, 25). ▪ = mean values • = median values. 
 
 
 
 
Figure 18. IMRT Group. IFN-γ cytokine concentration (pg/ml) for all 
participants (n=40) at all time points (Day 0, 5, 25). ▪ = mean values • = median 
values. 
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5.2 Time (Dose) Effect 
In addition to observing no significance between the two groups, there was also 
no significant time effect for any of the cytokines when the two groups were examined 
separately. However, when the treatment groups were combined, a significant time effect 
was observed for IL-4, which significantly decreased from baseline to day 25 (Figure 19). 
Further, the effect size of this difference was calculated 0.3. Similar results were found 
for INF-γ with a significant time effect (p<0.05) and a difference from baseline to day 25 
of about 2% (Figure 19), and a small effect size of 0.24. According to Table 4 below, 
there was no significant time effect for the other cytokines. 
 
Table 4. Time effects on the circulating pro-inflammatory markers (cPIC) in 
the total sample (both groups combined) with post hoc pairwise comparisons. 
cPIC 
Markers 
Time Points (days) 
χ2 (DF) 
p-value, N 
Day 0 Day 5 Day 25 
Mean ± SEM 
Median, N 
Mean ± SEM 
Median, N 
Mean ± SEM 
Median, N 
IL-4 
41.9 ± 4.7 
29.2, 62 
40.8 ± 5.4 
25.4, 65 
36.3 ± 4.1 
24.4, 63 a 
6.80 (2)  
0.03*, 58 
IL-6 
3.0 ± 0.3  
2.2, 56 
2.8 ± 0.3 
2.2, 60 
3.2 ± 0.4 
2.1, 61 
0.27 (2)  
0.87, 50 
IL-8 
6.1 ± 1.3  
3.8, 71 
5.4 ± 0.9 
3.8, 73 
6.6 ± 1.3 
4.2, 72 
3.79 (2)  
0.15, 68 
IL-10 
17.2 ± 1.9 
13.2, 42 
16.5 ± 2.2 
10.8, 44 
15.7 ± 1.8 
10.0, 40 
1.19 (2)  
0.55, 32 
TNF-α 
4.3 ± 0.4  
3.7, 63 
4.4 ± 0.4 
3.6, 63 
4.3 ± 0.4 
3.6, 62 
0.21 (2)  
0.90, 52 
INF-γ 
13.6 ± 1.7  
9.3, 68 
13.5 ± 1.8 
9.5, 72 
13.3 ± 1.7 
9.2, 68b 
7.52 (2)  
0.02*, 64 
* = statistical significance p<0.05 (Friedman test) 
a = statistical significance from baseline p=0.047 (Wilcoxon Signed Rank Test) 
b = statistical significance from baseline p=0.044 (Wilcoxon Signed Rank Test) 
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Figure 19. IL-4 and INF-γ levels at day 0 (baseline), 5 and 25. Mean (SEM) values, 
*statistical significance (p<0.05) from baseline (Wilcoxon comparisons). 
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CHAPTER 6: DISCUSSION 
 
To the best of our knowledge, this is the first study within a randomized trial that 
examined whether: i) pelvic radiation therapy for high risk prostate cancer influences the 
levels of circulating cytokines, and ii) whether there are differences in the levels of 
circulating cytokines between groups of patients treated with 3D-CRT vs. IMRT. The 
most significant finding was that the circulating pro-inflammatory cytokine concentration 
levels did not differ between the 3D-CRT and IMRT groups at any of the experimental 
time periods, i.e., day 0 (pre-treatment), or after either 5 days or 25 days of treatment. In 
addition, both IL-4 and INF-γ significantly decreased from baseline to day 25 when the 
results from both radiation therapy groups were combined. 
  
6.1 Baseline Levels of Pro-inflammatory Cytokines 
As shown in Table 6, certain cytokines were already elevated at baseline 
compared to healthy population cohorts. Specifically, IL-4 was much higher in our 
patients compared to healthy men in previous studies (30,31,39). Likewise, our patients’ 
IL-10 baseline levels were higher than the serum concentrations reported for a healthy 
Korean cohort of mixed gender (48). For the remaining cytokines, our baseline values 
were similar to those previously reported in healthy men and prostate cancer patients 
(Tables 6 and 7). According to previous studies, many cytokines are elevated in the 
plasma of patients with various cancers, and are produced by various neoplasms in vitro, 
including prostate cancer. On the other hand, our study shows a considerable variability 
in the baseline cytokine levels (Figures 7-18), but these levels are not significantly altered 
by radiation therapy. In addition, it has been suggested that some cytokines may suppress 
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or change the response of other cytokines (42). This could be taking place in patients 
receiving radiation therapy and may have influenced the responses we observed in our 
study. Indeed, a small number of patients, we can see changes in some cytokines such as 
TNF-α (Figures 15 and 16). 
 
Table 5. Circulating pro-inflammatory markers (cPIC) levels in healthy adults. 
 Healthy Cohorts  
 
Kim et al. (48)1 Chapman 
et al. (49)2 
Lopes 
et al. 
(30)3 
Johnke et 
al. (31)4 
Abdel-
Messeih et 
al. (39) 
cPIC 
Mixed 
Gender  
(<45 years) 
Mean±SEM 
(N=55) 
Mixed 
Gender  
(>65 years) 
Mean±SEM 
(N=55) 
Mixed 
Gender  
Mean 
(N=66) 
Males 
range 
Males 
Mean 
(N=15) 
Males 
Mean±SD 
(N=20) 
 
IL-4 
(pg/ml) 
- - 0.10 0-13.1 - 3.52±0.3 
IL-6 
(pg/ml) 
2.91 ± 0.9    2.57 ± 0.7    0.73 - ~1.2 - 
IL-8 
(pg/ml) 
23.9 ± 4.0             27.6 ± 5.9             7.21 - - - 
IL-10 
(pg/ml) 
1.32 ± 0.4 1.58 ± 0.8 0.13 - - - 
TNF-α 
(pg/ml) 
3.21 ± 0.5 4.94 ± 0.6 5.92 0-20 - - 
IFN-γ 
(pg/ml) 
13.1 ± 3.0 10.3 ± 2.5 13.43 - - 11.38 ± 1.2 
1Korean ethnicity; 2 No SEM reported, healthy subjects from all ages and ethnicities;  
3 Only a normal range provided for IL-4 and TNF-α; 4Approximated from graph, age range 53-79 years.  
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Table 6. Circulating pro-inflammatory markers (cPIC) levels in prostate cancer 
patients. 
 Studies in Prostate Cancer Patients 
 
Present 
Study 
Christensen 
et al. (28)1 
 
Lopes et al. 
(30)2 
 
Johnke et 
al. (31)3 
 
Abdel-
Messeih et 
al. (39) 
cPIC 
Mean±SEM 
(N=75) 
 Mean 
(N=42) 
 Mean±SEM 
(N=48) 
 Mean 
(N=37)  
 Mean±SEM 
(N=20)  
IL-4 (pg/ml) 41.9 ± 4.7 - 3.5 ± 1.2 - 7.72 ± 0.65 
IL-6 (pg/ml) 3.0 ± 0.3 ~1.5-2.0 ~3.7-7.7 ~1.6-2.7 - 
IL-8 (pg/ml) 6.1 ± 1.3 ~12.0 - - - 
IL-10 (pg/ml) 17.2 ± 1.9 ~4.0 - - - 
TNF-α 
(pg/ml) 
4.3 ± 0.4 ~10.0 11.7 ± 3.5 - - 
IFN-γ 
(pg/ml) 
13.6 ± 1.7 ~0.5-1.0 - - 8.86 ± 0.61 
1Approximated from graphs, no tabulated data provided, no SEM reported; 2 Range for IL-6 
approximated from graphs; 3 Approximated from graphs;  
 
6.2 Circulating Pro-inflammatory Cytokines in 3D-CRT vs. IMRT 
Treatments  
The findings did not support the hypothesis that cytokine levels would differ 
between the two radiation treatment protocols, as no statistical differences (p>0.05) were 
found between the groups at any time point (day 0, 5, and 25). The hypothesis stated that 
cytokine levels would be higher with the 3D-CRT protocol because one of the advantages 
of IMRT compared to 3D-CRT is the better dosage conformation around the prostate and 
surroundings organs. However, the IMRT patients had higher concentration levels in 
most of the circulating pro-inflammatory cytokines markers (except IL-4 and IL-8) 
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compared to the 3D-CRT group, at all the 3 times points, but the observed differences 
were not statistically significant. 
To our knowledge, there are no other prostate cancer studies that have compared 
cytokine concentrations between 3D-CRT and IMRT patients. Previous studies have 
compared 3D-CRT and IMRT patients in terms of toxicity and dosimetry, but did not 
measure cytokine levels (12,21,37). 
 
6.3 Time (Dose) Effect of Radiation Therapy on Circulating Cytokines 
Since there were no statistical differences in the cytokine concentrations between 
the groups across all time points, the groups were combined for the repeated measures 
analysis. A significant time effect was found for IL-4 and INF-γ, with post hoc pair-wise 
analysis showing a significant decrease at day 25 compared to baseline (p<0.05). 
Previously, Lopes et al. found only an increase in IL-6 during radiation therapy in 
patients with prostate cancer, with no change in IL-2, IL-4, IL-5, TNF-α, leukemia 
inhibitory factor, and macrophage inflammatory protein 1-α (30). Likewise, in the study 
of Chistensen et al., no significant difference (p>0.05) was observed in cytokines, 
including granulocyte macrophage colony stimulating factor, IL-10, IL-1α, IL-2, IL-6, 
IL-8, and TNF-α, before and during radiation therapy in a definitive (intact prostate) 
group receiving IMRT. However, when combined with a post-operative IMRT group, 
there was a significant increase in IL-6 and IFN-γ (p<0.05), which is in contrast to our 
study where IFN-γ significantly decreased 25 days into treatment (28).  
 
 
43 
 
6.3.1 IL-4 
IL-4 has an important role in regulating inflammatory and cell-mediated immune 
responses. IL-4 acts as an immune-suppressor of cancer immunity and promotes cancer 
develop-ment. In the past, only a few studies have investigated serum IL-4 levels in 
prostate cancer patients. It has been suggested that elevated IL-4 may be linked to disease 
evolution to castrate resistance (38). Abdel-Messeih et al. recently evaluated 20 patients 
with prostate cancer, who were subjected to radiation therapy post-prostatectomy, with a 
total dose of 66 Gy in 33 fractions (5 sessions/week) for 7 weeks. The level of 
inflammatory cytokines IL-4, IL-5 and INF-γ in post-radiation therapy patients were 
significantly elevated compared to both controls and prostate cancer patients (39). Our 
study, on the other hand, found a significant time effect for IL-4 during radiation therapy, 
which decreased 25 days into treatment. Cytokine production is time-dependent, peaking 
usually at 4–24 hours after irradiation, followed by a subsequent decrease to baseline 
levels within 24 hours to a few days for some type of cancers (38). 
6.3.2 TNF-α 
Since TNF-α has been shown to be expressed by prostate cancer (40), and plays a 
major role in the inflammatory process, we would have expected TNF-α to increase 
significantly during radiation therapy. However, neither our study, nor the study of Lopes 
et al. (30), found an increase in TNF-α during radiation therapy. In addition, Lopes et al., 
in their examination of IL-6, IL-2, IL-4, IL-5, TNF-α, macrophage inflammatory protein 
1-α, and leukemia inhibitory factor levels of prostate cancer patients treated with 3D-
CRT, found a significant increase of IL-6. They speculated that because IL-6 has also 
been described as an anti-inflammatory cytokine that suppresses the activity of pro-
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inflammatory mediators, the rise of IL-6 levels following radiation therapy could have 
been responsible for the suppression of other cytokines associated with the acute phase 
reaction (30). 
6.3.3 IL-6 
Jonke et al., in their examination of the circulating levels of IL1-β, IL-6 and TGF-
β in prostate cancer, compared the cytokines levels between a group treated with 
radiation therapy alone, a group treated with radiation therapy plus androgen therapy, and 
a healthy control group (31). They found that IL6 and IL-1β increased immediately 
during radiation therapy for both the radiation therapy groups, with and without androgen 
deprivation therapy. These cytokines peaked after 1 to 2 weeks of radiation therapy 
before returning to pre-therapy levels. They also observed an immediate decrease in 
TGF-β during radiation therapy, with two distinct waves of elevation, one at 1-2 weeks, 
and a second, 5-6 weeks into the radiation therapy (31). Lopes et al. found a significant 
rise for IL-6 at day 15 of radiation therapy (p<0.0049) and a decline at day 30, to levels 
similar to pre-treatment levels (30). Kovacs et al. described the elevated levels of 
cytokines in prostate cancer patients receiving radiation therapy in the form of cyclic 
waves, that were associated with accumulating doses of radiation therapy (26). However, 
none of these effects were observed in our cohort of patients receiving either IMRT or 
3D-CRT treatment. 
In our study, we selected two-time points during radiation therapy based on 
descriptions of both early and late waves of circulating cytokine expression during pelvic 
radiation in other studies (28,31). The study by Christensen et al. obtained blood samples 
every week during radiation therapy, but their study didn’t find any significant changes in 
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cytokine expression during radiation therapy for an “intact” prostate group treated with 
IMRT (28). Thus, the cyclic wave response of cytokine expression during radiation 
therapy appears to indicate that more frequent measurements of cytokine concentrations 
need to occur if we are to understand this time dependant response. 
One limitation of our study is that having only two-time measurements (days 5 
and 25 of treatment) may have not produced the resolution in time needed to capture 
these responses. The incentive for this choice of sampling times was to determine 
whether, i) early cytokine levels could predict radiation therapy toxicity and ii) whether 
cytokine levels at the time of completion of radiation therapy correlate with toxicity. 
Likewise, DiMaggio and colleagues also found that men with prostate cancer undergoing 
long-term androgen deprivation therapy did not demonstrate elevated levels of 
inflammatory cytokines compared to age and disease-matched controls (41).  
Johnke et al. (31) compared two groups of prostate cancer patients undergoing 
radiation therapy: one group with androgen deprivation therapy, and a second group 
without androgen deprivation therapy. They examined different cytokine levels and 
found that following initiation of radiation therapy, both patient groups demonstrated an 
immediate elevation of the pro-inflammatory cytokines IL-1β and IL-6 in their plasma. 
They described that the magnitude of cytokine expression was noticeably different in the 
group that received androgen deprivation therapy. More specifically, mean plasma levels 
of IL-1β and IL-6 significantly were significantly elevated following two months of ADH 
when compared to pre ADH values (31). However, Lopes et al. didn’t find any 
significance differences in cytokine levels, except for the IL-6. They explained that one 
possibility might be the concurrent hormone therapy (30), suggesting that the magnitude 
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of the cytokine levels in patients with prostate cancer treated with radiation therapy 
appeared to be affected by the addition of the hormone therapy. Our study was not 
designed to investigate the impact of androgen deprivation therapy, but rather the effects 
of the radiation therapy in patients that receive this treatment. However, in future studies, 
it would be useful to collect blood samples from the patients before initiating the 
androgen deprivation therapy.  
  
6.4 Strengths and Limitations  
To our knowledge, this is the first study to examine the response of cytokine 
expression from prostate cancer patients treated with either 3D-CRT vs. IMRT. The study 
has a number of strengths and limitations that are important to discuss, and are 
noteworthy for planning future studies. 
In terms of strengths, randomized trials are considered the gold standard for 
clinical study design in that such a design reduces selection bias. Patients participating in 
this trial were randomly allocated to either 3D-CRT or IMRT. A second strength was the 
relatively large sample size. Previous studies describing the role of circulating pro-
inflammatory cytokines during radiation therapy on prostate cancer have used smaller 
sample sizes. 
The large individual variability in the cytokine concentrations at baseline could be 
considered a limitation. Furthermore, we found that the levels of two cytokines (IL-4 and 
IL-10) were already significantly elevated compared to levels found in normal, healthy 
men of this age group. It is possible that these elevated levels may have altered the 
immune response of the patients to the radiation therapy. According to previous studies, 
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many cytokines are elevated in the plasma of patients with various cancers, including 
prostate cancer, and that the levels are relatively invariant during radiation therapy (26, 
40). In addition, it has been suggested that some cytokines may suppress or change the 
response of other cytokines (30), which may have influenced the responses we observed 
in our study. 
Potential confounders in our study include lifestyle choices, medications and 
comorbidities. These conditions, which have been previously found to contribute to 
systemic inflammation (e.g., severe osteoarthritis or connective tissue disorders), can 
impact baseline cytokine variability (33). For example, Druzgal et al. reported increases 
in IL-6 and hepatocyte growth factor (HGF) in cancer patients who relapsed, but also in 
patients who had developed inflammatory conditions. In addition, longitudinal increases 
in serum IL-6, IL-8, vascular endothelial growth factor, and human growth factor have 
been significantly associated with a decreased cause-specific survival in patients with 
locally advanced oropharyngeal squamous cell carcinoma (27). For instance, a number of 
patients smoked during and after treatment. The impact of this habit or other co-
morbidities, on inflammatory cytokines like IL-6 or IL-8, was not accounted for (43).  
 In terms of design limitations, an ideal design would include a healthy, age 
and weight-matched control group to make comparisons between the healthy population 
and cancer patients. Secondly, since cytokine levels behave in the form of cyclic waves 
(26,31), additional time points would allow better characterization of the cytokine 
response. However, since every study seemed to measure the cytokine concentrations at 
different time points, it was difficult to ascertain the appropriate time points during 
radiation therapy to take the blood samples. However, since every study seemed to 
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measure the cytokine concentrations at different time points, it was difficult to ascertain 
the appropriate time points during radiation therapy to take the blood samples. Lastly, it 
would have been ideal to collected blood samples before androgen therapy in order to 
understand how hormonal therapy affects the cytokine expression.  
 
 
  
49 
 
CHAPTER 7: CONCLUSIONS AND 
RECOMMENDATIONS 
In recent years, studies have focused on elucidating clinically useful biomarkers 
of radiation therapy-induced toxicity, with the goal of identifying a patient’s radio-
sensitivity profile, which could lead to the development of personalized treatments, and 
ultimately, to improved local control of radiation to minimize tissue damage in 
surrounding tissues, and improved quality of life.  
The concept of investigating the levels of circulating pro-inflammatory cytokines 
as potential biomarkers of inflammation and radiation toxicity is well supported by a 
significant number of clinical studies. Unfortunately, it is difficult to compare, and to 
draw conclusions from these previous due to differences in methodological design, 
subject pools, investigative techniques, and findings. As a result, it has not been possible 
to get a complete picture of the response of circulating pro-inflammatory cytokines to 
radiation therapy, and therefore, their potential as useful biomarkers of toxicity.  
The present study was undertaken as part of a larger clinical trial aimed at 
examining the efficacy of IMRT as the protocol of choice in the treatment of prostate 
cancer. The work described here was designed to examine the response of various 
cytokines to radiation therapy, and to examine the levels of circulating cytokines in 
relation to radiation protocol (IMRT vs. 3D-CRT), radiation dose to the prostate, nodal 
areas, and normal tissues, as well as measures of patient quality of life. To this end, we 
utilized a randomized, control trial, that involved 75 patients, divided into two groups, 
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and assessed cytokine levels at 3 time points, namely, before and during the radiation 
therapy. 
Our study suggests that, in high risk prostate cancer patients, who are treated with 
androgen deprivation therapy, there is no statistically significant difference in the mean 
levels of circulating pro-inflammatory cytokines between patients receiving radiation 
treatment via 3D-CRT vs IMRT. However, an analysis of the pooled data from all 
patients revealed statistically significant changes over time, which indicated that IL-4, 
and perhaps IFN-γ, decreased with cumulative radiation therapy dose, independent of 
radiation therapy technique.  
The present study was not able to observe any significant evidence that radiation 
therapy technique modulates cytokine levels in this group of patients. Often, a low 
statistical power, due to a small sample size, is the reason for an inability to detect 
significant differences in results; however, the present study is one of the largest to date 
to measure cytokine expression on prostate cancer patients treated with 3D-CRT vs. 
IMRT, and thus, should have provided adequate statistical power.  
Another issue that influences the potential to find statistical differences involves 
an increased variability in the data due to biological variation between subjects, 
differences in their response to a perturbation of the system, and our inability to detect 
change. The issues to examine here include i) higher cytokine levels at baseline (time 0), 
ii) differences in the cytokine response to variations in radiation dose, iii) sub-optimal 
times of sampling, both in terms of diurnal variation, and in the choice of time points 
during treatment, and iv) a mismatch between the sensitivity of the biochemical assay to 
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detect changes in the levels of the cytokines compared to the actual changes that 
occurred. 
At present, the cytokine response to radiation therapy is poorly understood. As 
indicated above, the gathering and analyzing of data concerning the cytokine expression 
in patients receiving radiation therapy is complicated by several factors. Future studies 
should control for the following: i) the effects of baseline characteristics of the patient 
population, such as age, differences in the tumor burden and medical comorbidities, ii) 
diurnal variations in cytokines levels, iii) ongoing patho-physiological stressors, 
including infection, cancer, and trauma, and iv) the use of prescribed and non-
prescription medications, especially anti-inflammatory drugs. Further, we need to 
determine the impact of other confounders, including age, radiation-induced changes in 
patient weight, the use of androgen hormone therapy as part of the treatment regimen, 
and overall individual patient radio-sensitivity.  
It is anticipated that the results of the present study will provide evidence whether 
cytokine levels at baseline, or during radiation therapy are associated with radiation 
therapy toxicity, the efficacy of the IMRT protocol (compared to the 3D-CRT protocol), 
and the relationship of cytokines as a biomarker that might be used to develop individual 
radiation therapy protocols to enhance the patients’ quality of life.  
In conclusion, this study has provided novel information concerning cytokine 
responses to radiation therapy. Future trials will need to address the concerns raised 
above, including sample size, control groups, well defined criteria for sampling periods 
and protocols based on the normal diurnal variation of cytokines, and improved 
biochemical assays with an increased sensitivity to the changes in cytokine level, will 
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allow future researchers to ascertain the efficacy of assessing cytokine responses as a tool 
for improving the potential role of cytokines as biomarkers of radiation therapy toxicity 
in patients treated for prostate cancer. 
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APPENDIX 3. SPSS Statistics Raw Output 
 
Wilcoxon Signed Ranks Test 
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Ranks 
 N 
Mean 
Rank 
Sum of 
Ranks 
IL4_D5 - 
IL4_D0 
Negative 
Ranks 
36a 27.89 1004.00 
Positive Ranks 22b 32.14 707.00 
Ties 1c   
Total 59   
IL4_D25 - 
IL4_D0 
Negative 
Ranks 
38d 29.25 1111.50 
Positive Ranks 20e 29.98 599.50 
Ties 1f   
Total 59   
a. IL4_D5 < IL4_D0 
b. IL4_D5 > IL4_D0 
c. IL4_D5 = IL4_D0 
d. IL4_D25 < IL4_D0 
e. IL4_D25 > IL4_D0 
f. IL4_D25 = IL4_D0 
 
 
Test Statisticsa 
 
IL4_D5 - 
IL4_D0 
IL4_D25 - 
IL4_D0 
Z -1.150b -1.982b 
Asymp. Sig. (2-tailed) .250 .047 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
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Ranks 
 N 
Mean 
Rank 
Sum of 
Ranks 
IFNy_D5 - 
IFNy_D0 
Negative 
Ranks 
37a 31.42 1162.50 
Positive Ranks 28b 35.09 982.50 
Ties 2c   
Total 67   
IFNy_D25 - 
IFNy_D0 
Negative 
Ranks 
43d 32.09 1380.00 
Positive Ranks 22e 34.77 765.00 
Ties 0f   
Total 65   
IFNy_D25 - 
IFNy_D5 
Negative 
Ranks 
39g 33.97 1325.00 
Positive Ranks 26h 31.54 820.00 
Ties 2i   
Total 67   
a. IFNy_D5 < IFNy_D0 
b. IFNy_D5 > IFNy_D0 
c. IFNy_D5 = IFNy_D0 
d. IFNy_D25 < IFNy_D0 
e. IFNy_D25 > IFNy_D0 
f. IFNy_D25 = IFNy_D0 
g. IFNy_D25 < IFNy_D5 
h. IFNy_D25 > IFNy_D5 
i. IFNy_D25 = IFNy_D5 
 
Test Statisticsa 
 
IFNy_D5 - 
IFNy_D0 
IFNy_D25 - 
IFNy_D0 
IFNy_D25 - 
IFNy_D5 
Z -.588b -2.009b -1.650b 
Asymp. Sig. (2-
tailed) 
.556 .044 .099 
a. Wilcoxon Signed Ranks Test 
b. Based on positive ranks. 
 
